Loading…
← CockpitCompetitor Analysis › 9688.HK Zai Lab Ltd.Open in the cockpit ↗

Zai Lab Ltd.9688.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Shanghai-based biopharma that licenses and co-develops oncology, autoimmune and infectious-disease drugs for the China market.

≈ A China-focused commercial biopharmaMomentum strong 78
Mkt cap
$2.79B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$12.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-145.8 pp
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · HKDHK$17.87
1D-4.8%
1W-12.7%
1M-5.2%
3M-12.1%
6M+22.7%
YTD+30.9%
1Y+3.4%
ATR %5.9%
52w lowhigh16.9% off high

What Zai Lab does

Shanghai-based biopharma that licenses and co-develops oncology, autoimmune and infectious-disease drugs for the China market.

Licenses the rights to drugs from Western and other developers for China, registers them locally and sells them through its own sales force to hospitals, paying royalties and milestones back to the originators. It is incorporated in the Cayman Islands and also trades in the US as ADRs.

In one line: A China-focused commercial biopharma.

Products and services

  • Zejula (oncology)
  • Optune (glioblastoma device)
  • Nuzyra (antibiotic)
  • Pipeline: autoimmune & cell therapy

Customers

  • Hospitals & oncologists in China

Where it sits in the supply chain

  • Biopharmaceuticals
  • In-licensing & local development
  • Commercialization in China

What could go right

  • China oncology drug market growth
  • New drug approvals/launches

What could go wrong

  • China drug pricing/procurement pressure
  • Licensing/royalty cost structure

Moat: narrow (regulatory licence, distribution). Strong China commercial/regulatory network to launch licensed drugs, but pays royalties to originators.

Headquarters: Shanghai, China · Founded: 2013 · Employees: 1,784

Named competitors

Zai Lab at a glance

Size Zai Lab (9688.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $2.79B, the 344th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$17.87 on 18 Nov 2026.

Performance Over six months the shares gained 22.7%, against -5.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 0.3% over the last twelve months (peer median +5.3%); the operating margin is -63.0% (peer median -0.7%).

Valuation It trades at 5.4× enterprise value to sales against a peer median of 9.4× (6th cheapest of 18).

Capital Return on invested capital runs 145.8 points below its cost of capital (10.5% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 20269688.HK 125Peer median 96
Six months, rebased to 100: Zai Lab against the median of its 20 peers (local-currency closes).

Zai Lab financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$3.45BHK$3.59BHK$3.11BHK$2.09BHK$1.68B
Revenue growth—+15%+49%+24%—
Gross profitHK$1.89BHK$2.10BHK$1.96BHK$1.34BHK$1.10B
EBITDA-HK$2.00B-HK$1.60B-HK$2.04B-HK$2.81B-HK$3.04B
Net income-HK$1.55B-HK$1.37B-HK$2.01B-HK$2.62B-HK$3.47B
Free cash flow-HK$1.26B-HK$1.24B-HK$1.73B-HK$1.61B-HK$3.07B
Capital expenditureHK$301MHK$105MHK$480MHK$66.5MHK$196M
Total debtHK$2.10BHK$1.75BHK$1.19BHK$118MHK$159M

Quarterly statements and history in the cockpit →

Zai Lab competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%BAVA68872228028300MBXRUBICONDNLITLXXNCRADMA688278XERS300142VIRPELVN300255RCUS9688.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Zai Lab is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×2,000×4,000×6,000×BAVA68872228028300RUBICONADMAXERS3001420020076919RCUS9688.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zai Lab is the large dot.

Zai Lab competitors and peer comparison

Head to head with its named competitors (9688.HK vs 1801.HK vs 688235.SS vs 1877.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Zai Lab 9688.HK$2.79B+23%0%-63%5.4×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
BeOne Medicines 688235.SS$45.5B+9%+25%18%6.3×19.1%
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%8.4×n/a
Keymed Biosciences 2162.HK$2.39B+7%0%-73%16.8×n/a
Everest Medicines 1952.HK$1.05B-20%+193%-5%3.0×n/a
Akeso 9926.HK$7.01B-48%+42%-25%12.9×n/a
Hansoh Pharma 3692.HK$25.3B-3%+25%38%9.0×7.9%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
Cspc Pharma 1093.HK$12.0B+10%+25%28%2.1×-10.7%

How Zai Lab compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zai Lab against its 20 peers (data as of 18 Nov 2026)
Measure9688.HKPeer medianRank in peer set
1-month return-5.2%-4.6%11th highest of 21
6-month return+22.7%-5.6%7th highest of 21
Distance from 52-week high-16.9%-31.6%6th highest of 21
Revenue growth (TTM)+0.3%+5.3%7th lowest of 17
Operating margin-63.0%-0.7%7th lowest of 18
EV / Sales5.4×9.4×6th cheapest of 18
ROIC minus cost of capital-145.8 pp-6.1 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a

Questions

Who are Zai Lab's main competitors?
Named competitors: Innovent Biologics (1801.HK), BeiGene (688235.SS), Junshi Biosciences (1877.HK), Hutchmed (2162.HK), Everest Medicines (1952.HK), Akeso (9926.HK). The cockpit's measured peer set (industry) also includes Bavarian Nordic A/S (BAVA.CO), Sunshine Lake Pharma (6887.HK), XtalPi (2228.HK), HLB (028300.KS), MBX Biosciences (MBX), Rubicon Research (RUBICON.NS).
Is Zai Lab expensive compared with its peers?
On ev / sales it trades at 5.4× against a peer median of 9.4×, 6th cheapest of 18 in its peer set.
How has Zai Lab stock performed?
Over six months to 18 Nov 2026 the shares returned +22.7% against -5.6% for the median peer; over one year +3.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.